Domenico Priolo

658 total citations
9 papers, 364 citations indexed

About

Domenico Priolo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Domenico Priolo has authored 9 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Cancer Research. Recurrent topics in Domenico Priolo's work include Lung Cancer Treatments and Mutations (3 papers), HER2/EGFR in Cancer Research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Domenico Priolo is often cited by papers focused on Lung Cancer Treatments and Mutations (3 papers), HER2/EGFR in Cancer Research (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). Domenico Priolo collaborates with scholars based in Italy and United States. Domenico Priolo's co-authors include Domenica Lorusso, Gabriella Ferrandina, Giovanni Scambia, Enrico Breda, Antonella Savarese, Dionyssios Katsaros, Laura Scaltriti, Pietro Del Medico, M. Ludovisi and Sandro Pignata and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Domenico Priolo

8 papers receiving 352 citations

Peers

Domenico Priolo

ONCOL

RM

SURGE

MB

PRM

Angeles A. Alvarez United States

Linn Woelber Germany

Alessandra Bologna Italy

L. Cannella Italy

W. ten Bokkel Huinink Netherlands

Daniel L. Spitz United States

Ondřej Kubeček Czechia

Ahmed Kamel Egypt

S. Loibl Germany

Perrine Garde‐Granger Canada

Angeles A. Alvarez United States

Domenico Priolo

136 ×0.8

ONCOL

188 ×1.1

RM

108 ×1.1

SURGE

163 ×1.8

MB

72 ×1.2

PRM

Citations per year, relative to Domenico Priolo Domenico Priolo (= 1×) peers Angeles A. Alvarez

Countries citing papers authored by Domenico Priolo

Since Specialization

Citations

This map shows the geographic impact of Domenico Priolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Domenico Priolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Domenico Priolo more than expected).

Fields of papers citing papers by Domenico Priolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Domenico Priolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Domenico Priolo. The network helps show where Domenico Priolo may publish in the future.

Co-authorship network of co-authors of Domenico Priolo

This figure shows the co-authorship network connecting the top 25 collaborators of Domenico Priolo. A scholar is included among the top collaborators of Domenico Priolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Domenico Priolo. Domenico Priolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Russo, Alessia, Domenico Priolo, Giovanna Antonelli, et al.. (2017). Bevacizumab in the treatment of NSCLC: patient selection and perspectives. PubMed. Volume 8. 259–269. 48 indexed citations

2.

Russo, Alessia, Francesco Ferraù, Giovanna Antonelli, et al.. (2014). Malignant melanoma in elderly patients: biological, surgical and medical issues. Expert Review of Anticancer Therapy. 15(1). 101–108. 27 indexed citations

3.

Adamo, Vincenzo, Vito Lorusso, Rosalba Rossello, et al.. (2008). Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. British Journal of Cancer. 98(12). 1916–1921. 20 indexed citations

4.

Ferrandina, Gabriella, M. Ludovisi, Domenica Lorusso, et al.. (2008). Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. Journal of Clinical Oncology. 26(6). 890–896. 220 indexed citations

5.

Antonelli, Giovanna, et al.. (2006). Locally advanced non-small cell lung cancer: different strategies for different diseases. Annals of Oncology. 17. ii24–ii27.

6.

Morabito, Alessandro, Domenico Gattuso, Simonetta Chiara Stani, et al.. (2004). Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer. Breast Cancer Research and Treatment. 86(3). 249–258. 24 indexed citations

7.

Cascinu, Stefano, Roberto Labianca, Vincenzo Catalano, et al.. (2003). Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology. 14(2). 205–208. 22 indexed citations

8.

Amadio, Placido, et al.. (2003). 795 Vinorelbin (VNB) and gemcitabine (gem) in unfit or elderly patients (pts) affected by advanced non small cell lung cancer (NSCLC): may sequential administration. European Journal of Cancer Supplements. 1(5). S239–S239. 1 indexed citations

9.

Bordonaro, Roberto, et al.. (1999). Fludarabine Phosphate as an Active and Well Tolerated Salvage Therapy in an Elderly Heavily Pretreated Hodgkin's Disease Patient: A Case Report. Tumori Journal. 85(4). 288–289. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact